| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Inhibikase Therapeutics, Inc. | Director | Common Stock | 145,000 | $198,650 | $1.37 | 21 Oct 2024 | Direct |
| RayzeBio, Inc. | CHIEF FINANCIAL OFFICER | Common Stock | 0 | $0 | $62.50 | 26 Feb 2024 | Direct |
| Inhibikase Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 108,176 | 30 Jun 2025 | Direct | ||
| RayzeBio, Inc. | CHIEF FINANCIAL OFFICER | Employee Stock Option (right to buy) | 0 | 26 Feb 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| IKT | Inhibikase Therapeutics, Inc. | 30 Jun 2025 | 1 | $0 | 4 | Director | 02 Jul 2025, 19:41 |
| IKT | Inhibikase Therapeutics, Inc. | 14 Feb 2025 | 2 | $0 | 4 | Director | 19 Feb 2025, 20:19 |
| IKT | Inhibikase Therapeutics, Inc. | 21 Oct 2024 | 2 | +$198,650 | 4 | Director | 23 Oct 2024, 19:49 |
| IKT | Inhibikase Therapeutics, Inc. | 21 Oct 2024 | 0 | $0 | 3 | Director | 23 Oct 2024, 19:40 |
| RYZB | RayzeBio, Inc. | 26 Feb 2024 | 4 | -$4,902,062 | 4 | CHIEF FINANCIAL OFFICER | 27 Feb 2024, 16:42 |
| RYZB | RayzeBio, Inc. | 17 Nov 2023 | 1 | $0 | 4 | Chief Financial Officer | 17 Nov 2023, 18:38 |
| RYZB | RayzeBio, Inc. | 14 Sep 2023 | 0 | $0 | 3 | Chief Financial Officer | 14 Sep 2023, 20:39 |